Zynerba Pharmaceuticals, Inc. (ZYNE): Price and Financial Metrics


Zynerba Pharmaceuticals, Inc. (ZYNE): $0.85

0.03 (+3.71%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ZYNE Stock Price Chart Interactive Chart >

Price chart for ZYNE

ZYNE Price/Volume Stats

Current price $0.85 52-week high $4.62
Prev. close $0.82 52-week low $0.82
Day low $0.85 Volume 197,500
Day high $0.88 Avg. volume 487,686
50-day MA $1.15 Dividend yield N/A
200-day MA $1.72 Market Cap 38.91M

Zynerba Pharmaceuticals, Inc. (ZYNE) Company Bio


Zynerba Pharmaceuticals is a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The company was founded in 2007 and is based in Devon, Pennsylvania.


ZYNE Latest News Stream


Event/Time News Detail
Loading, please wait...

ZYNE Latest Social Stream


Loading social stream, please wait...

View Full ZYNE Social Stream

Latest ZYNE News From Around the Web

Below are the latest news stories about ZYNERBA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ZYNE as an investment opportunity.

Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference

DEVON, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, at 3:00 p.m. ET, and host investor meetings. The conference is being held at the So

Yahoo | September 22, 2022

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium

INSPIRE trial in 22q achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments, with excellent tolerability profileDEVON, Pa., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, announces an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th Interna

Yahoo | September 8, 2022

Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference

DEVON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present in-person at the H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022, at 2:00 p.m. ET, and host investor meetings. The conference is

Yahoo | September 6, 2022

Zynerba Pharmaceuticals Announces Oral Presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium

DEVON, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the acceptance of an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium, which will be held in Oslo, Norway, September 8-10, 2022. A copy of the presentation slides will be made available on the Zynerb

Yahoo | August 31, 2022

Analysts Offer Insights on Healthcare Companies: Zynerba Pharmaceuticals (ZYNE) and Medios AG (OtherMEDOF)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zynerba Pharmaceuticals (ZYNE – Research Report) and Medios AG (MEDOF – Research Report) with bullish sentiments. Zynerba Pharmaceuticals (ZYNE) Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Zynerba Pharmaceuticals today and set a price target of $8.00. The company's shares closed last Wednesday at $1.25, close to its 52-week low of $0.84. According to TipRanks.

Christine Brown on TipRanks | August 11, 2022

Read More 'ZYNE' Stories Here

ZYNE Price Returns

1-mo -26.09%
3-mo -25.44%
6-mo -58.13%
1-year -81.03%
3-year -89.00%
5-year -89.83%
YTD -70.49%
2021 -12.73%
2020 -45.36%
2019 103.37%
2018 -76.28%
2017 -19.69%

Continue Researching ZYNE

Here are a few links from around the web to help you further your research on Zynerba Pharmaceuticals Inc's stock as an investment opportunity:

Zynerba Pharmaceuticals Inc (ZYNE) Stock Price | Nasdaq
Zynerba Pharmaceuticals Inc (ZYNE) Stock Quote, History and News - Yahoo Finance
Zynerba Pharmaceuticals Inc (ZYNE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5863 seconds.